Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)

Amgen Inc. (NASDAQ:AMGN) is one of the best medical research stocks to buy according to hedge funds. Amgen Inc. (NASDAQ:AMGN) received rating updates from Argus Research and Guggenheim on February 6. Argus reiterated a Buy rating on the stock with a $400 price target, while Guggenheim reaffirmed a Hold rating on Amgen Inc. (NASDAQ:AMGN) and set a price target of $347. RBC Lifts Amgen (AMGN) Target After Strong Q4, Cites Key Drug Momentum The rating updates came after Amgen Inc. (NASDAQ:AMGN) reported its ...